(TheNewswire)
Calgary, AB – TheNewswire - January 19, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weeklydefaultstatusreportupdate:
Further to the Company’s prior news release (January 5, 2024), the Company is providingthis bi-weeklydefaultstatusreport(the “Default Status Report”) inaccordancewithNationalPolicy12‑203Management CeaseTradeOrders(“NP12-203”).
OnNovember 20,2023,UIannouncedthat it would delay the filing of its annual audited financial statements for the year ended July 31, 2023, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2023.
The Company was granted a management cease trade order ("MCTO") by the Alberta Securities Commission, its principal regulator, on December 6, 2023 and UI is required to filebi-weeklydefaultstatusreportsintheformof a news releaseduringtheperiodoftheMCTO.FailuretofiletheRequired Filings orthe bi-weeklydefaultstatusreportswillresultintheissuanceof a generalceasetradeorder.
The Company intends to file the Required Filings, along with its unaudited interim financial statements and related MD&A for the Q1 interim period ended October 31, 2023, upon the pending completion of the audit of the consolidated financial statements for the year ended July 31, 2023 (the “Audit”). The audit continues to progress as expected and is planned to be completed by January 24, 2024.
At the request of the TSXV, UI advises that its previously announced private placement of common share “Units” (see News Release of May 19, 2023) was eventually terminated. The Company’s current private placement (see News Release of December 20, 2023) of common shares at a price of $0.01 per share is proceeding, and subject to TSXV approval, the Company intends to close shortly on initial funds for subscriptions it has received totalling approximately $417,000.
Pursuant to the provisions of the alternative information guidelines specified in NP 12-203, the Corporation reports that since its last news release of January 5, 2024, except as otherwise noted herein:
-
There have been no material changes to the information contained in the prior news releases / Default Status Report that would reasonably be expected to be material to an investor;
-
There have been no failures by the Company to fulfill its stated intentions with respect to satisfying the provisions of the alternative information reporting guidelines under NP 12-203;
-
There has not been, nor is there anticipated to be, any specified default subsequent to the default which is the subject of the Default Announcement; and
-
There is no other material information respecting the Company's affairs that has not been generally disclosed.
UI intends to comply with the provisions of the alternative information guidelines as set out in NP 12-203 for as long as it remains in default, by issuing bi-weekly default status reports, each of which will be issued in the form of a news release. The Company will also continue to disclose any other material information concerning its affairs and ongoing business activities.
This news release has been approved by the CEO of the Company.
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that treatment protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre (located near Winnipeg, Manitoba) that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as "plans", “planned”, "expect", "project", "intends", “intended” "will", "believe", "anticipate", "estimate", "scheduled", "potential", or other similar words, or statements that certain events or conditions "may", "should" or "could" occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI at the date the statements are made. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
Additional information identifying risks and uncertainties that could affect financial results and the Company is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com
For further information:
Nick Karos, CEO
Universal Ibogaine Inc.
612-309-3527
Nick.Karos@universalibogaine.com
Investor Relations: Dugan Selkirk, IR Manager
dugan.selkirk@universalibogaine.com
Related Links
https://universalibogaine.com
Copyright (c) 2024 TheNewswire - All rights reserved.